<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20031101//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2750750</article-id><article-id pub-id-type="pmid">19806184</article-id><article-id pub-id-type="publisher-id">09-PONE-RA-09005R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007302</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Pediatrics and Child Health</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">RTS,S/AS in Ghanaian Children</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Owusu-Agyei</surname><given-names>Seth</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ansong</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Asante</surname><given-names>Kwaku</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kwarteng Owusu</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Owusu</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wireko Brobby</surname><given-names>Naana Ayiwa</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dosoo</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Osei Akoto</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Osei-Kwakye</surname><given-names>Kingsley</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Adjei</surname><given-names>Emmanuel Asafo</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boahen</surname><given-names>Kwadwo Owusu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sylverken</surname><given-names>Justice</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Adjei</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sambian</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Apanga</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kayan</surname><given-names>Kingsley</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vekemans</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ofori-Anyinam</surname><given-names>Opokua</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leach</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lievens</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Demoitie</surname><given-names>Marie-Ange</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dubois</surname><given-names>Marie-Claude</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Joe</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ballou</surname><given-names>W. Ripley</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Savarese</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chandramohan</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gyapong</surname><given-names>John Owusu</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Milligan</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Antwi</surname><given-names>Sampson</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Agbenyega</surname><given-names>Tsiri</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Greenwood</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Kintampo Health Research Centre, Health Research Unit, Kintampo, Ghana</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>London School of Hygiene and Tropical Medicine, London, United Kingdom</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>GlaxoSmithKline Biologicals, Rixensart, Belgium</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Bill and Melinda Gates Foundation, Seattle, Washington, United States of America</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Health Research Unit, Ghana Health Service, Ministry of Health, Accra, Ghana</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Kumasi Centre for Collaborative Research, Kumasi, Ghana</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Doolan</surname><given-names>Denise L.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Queensland Institute of Medical Research, Australia</aff><author-notes><corresp id="cor1">* E-mail: <email>Seth.owusu-agyei@ghana-khrc.org</email></corresp><fn fn-type="con"><p><text><SENT sid="1" pm="."><plain>Conceived and designed the experiments: SOA DA KPA JV OOA AL ML MCD JC WRB BS TA BG JE. </plain></SENT>
<SENT sid="2" pm="."><plain>Performed the experiments: SOA DA KPA SKO RO NAWB DD AOA KOK EAA KOB JS GA DS SA KK MAD DC TA JE. </plain></SENT>
<SENT sid="3" pm="."><plain>Analyzed the data: SOA DA KPA JV OOA AL ML MAD MCD JC WRB BS DC JOG PJM SA TA BG JE. </plain></SENT>
<SENT sid="4" pm="."><plain>Contributed reagents/materials/analysis tools: ML MAD. </plain></SENT>
<SENT sid="5" pm="."><plain>Wrote the paper: SOA JV AL ML JC WRB BG. </plain></SENT>
<SENT sid="6" pm="."><plain>Revised and approved final version of the publication: SOA DA KPA SKO RO NAWB DD AOA KOK EAA KOB JS GA DS SA KK JV OOA AL ML MAD MCD JC WRB BS DC JOG PJM SA TA BG JE. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>10</month><year>2009</year></pub-date><volume>4</volume><issue>10</issue><elocation-id>e7302</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Owusu-Agyei et al.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="7" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>The target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Africa is the World Health Organisation Expanded Program on Immunization. </plain></SENT>
<SENT sid="9" pm="."><plain>As an Adjuvant System, age de-escalation and schedule selection step, this study assessed 3 schedules of RTS,S/AS01E and RTS,S/AS02D in infants and young children 5–17 months of age in Ghana. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Methodology </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>A Phase II, partially-blind randomized controlled study (blind to vaccine, not to schedule), of 19 months duration was conducted in two (2) centres in Ghana between August 2006 and May 2008. </plain></SENT>
<SENT sid="12" pm="."><plain>Subjects were allocated randomly (1∶1∶1∶1∶1∶1) to one of six study groups at each study site, each defining which vaccine should be given and by which schedule (0,1-, 0,1,2- or 0,1,7-months). </plain></SENT>
<SENT sid="13" pm="."><plain>For the 0,1,2-month schedule participants received RTS,S/AS01E or rabies vaccine at one center and RTS,S/AS01E or RTS,S/AS02D at the other. </plain></SENT>
<SENT sid="14" pm="."><plain>For the other schedules at both study sites, they received RTS,S/AS01E or RTS,S/AS02D. </plain></SENT>
<SENT sid="15" pm="."><plain>The primary outcome measure was the occurrence of serious adverse events until 10 months post dose 1. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="16" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>The number of serious adverse events reported across groups was balanced. </plain></SENT>
<SENT sid="18" pm="."><plain>One child had a simple febrile convulsion, which evolved favourably without sequelae, considered to be related to RTS,S/AS01E vaccination. </plain></SENT>
<SENT sid="19" pm="."><plain>Low grade reactions occurred slightly more frequently in recipients of RTS,S/AS than rabies vaccines; grade 3 reactions were infrequent. </plain></SENT>
<SENT sid="20" pm="."><plain>Less local reactogenicity occurred with RTS,S/AS01E than RTS,S/AS02D. </plain></SENT>
<SENT sid="21" pm="."><plain>Both candidate vaccines were highly immunogenic for anti-circumsporozoite and anti-Hepatitis B Virus surface antigen antibodies. </plain></SENT>
<SENT sid="22" pm="."><plain>Recipients of RTS,S/AS01E compared to RTS,S/AS02D had higher peak anti-circumsporozoite antibody responses for all 3 schedules. </plain></SENT>
<SENT sid="23" pm="."><plain>Three dose schedules were more immunogenic than 2 dose schedules. </plain></SENT>
<SENT sid="24" pm="."><plain>Area under the curve analyses for anti-circumsporozoite antibodies were comparable between the 0,1,2- and 0,1,7-month RTS,S/AS01E schedules. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="25" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="26" pm="."><plain>Both candidate malaria vaccines were well tolerated. </plain></SENT>
<SENT sid="27" pm="."><plain>Anti-circumsporozoite responses were greater with RTS,S/AS01E than RTS,S/AS02D and when 3 rather than 2 doses were given. </plain></SENT>
<SENT sid="28" pm="."><plain>This study supports the selection of RTS,S/AS01E and a 3 dose schedule for further development in children and infants. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="29" pm="."><plain>Trial Registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="30" pm="."><plain>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http:\\clinicaltrials.gov\ct2\show\NCT00360230">NCT00360230</ext-link> </plain></SENT>
</text></SecTag></p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="31" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>Plasmodium falciparum malaria is a major cause of human suffering and represents an important economic burden to sub-Saharan African countries [1], [2]. </plain></SENT>
<SENT sid="33" pm="."><plain>A safe and effective vaccine that prevents P. falciparum malaria would be an important addition to current control methods. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>The RTS,S malaria vaccine candidate (GlaxoSmithKline, Rixensart, Belgium), is formulated with proprietary Adjuvant Systems which enhance the ability of the vaccine to induce a strong immune response. </plain></SENT>
<SENT sid="35" pm="."><plain>The AS02 Adjuvant System contains an oil-in-water emulsion with monophosphoryl lipid A (MPL) and QS21, a natural saponin molecule purified from the bark of the South American tree Quillaja saponaria. </plain></SENT>
<SENT sid="36" pm="."><plain>The AS01 Adjuvant System is based on liposomes and contains the same amounts of MPL and QS21 as AS02. </plain></SENT>
<SENT sid="37" pm="."><plain>Both preclinical studies and field studies in adults have suggested that the AS01 formulation is more immunogenic than the AS02 formulation [3]–[5]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>AS01 and AS02 were initially developed as the adult formulations AS02A and AS01B (0.5 mL dose). </plain></SENT>
<SENT sid="39" pm="."><plain>For compatibility with standard auto-disable Expanded Program on Immunization (EPI) syringes, a 0.5 mL variant of the paediatric 0.25 mL dose of RTS,S/AS02A (RTS,S/AS02D) and of RTS,S/AS01B (RTS,S/AS01E) were developed. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>A large study with the paediatric dose (0.25 mL) of the adult formulation RTS,S/AS02A, conducted in Mozambican children aged 1–4 years, demonstrated the vaccine to have an acceptable safety profile and to be efficacious against clinical malaria (vaccine efficacy of 35%) and severe malaria disease (vaccine efficacy of 49%) over a period of 18 months [6]. </plain></SENT>
<SENT sid="41" pm="."><plain>Subsequently, non-inferiority of the RTS,S/AS02D formulation compared to a paediatric dose of RTS,S/AS02A was demonstrated with respect to anti-circumsporozoite (CS) and anti-Hepatitis B Virus surface antigen (HBs) antibodies in children aged 3 to 5 years from Mozambique [7]. </plain></SENT>
<SENT sid="42" pm="."><plain>Both vaccines were shown to have a similar safety profile. </plain></SENT>
<SENT sid="43" pm="."><plain>More recently, a similar safety profile of RTS,S/AS02D and RTS,S/AS01E was demonstrated in children aged 18 months to 4 years in Gabon [8]; a trend towards better anti-CS and anti-HBs responses with RTS,S/AS01E was observed. </plain></SENT>
<SENT sid="44" pm="."><plain>Following administration of RTS,S/AS02D at 8, 12 and 16 weeks of age to infants in Tanzania, RTS,S/AS02D had a promising safety profile, met pre-specified non-inferiority seroconversion rates for co-administered EPI antigens, and reduced the incidence of malaria infection (vaccine efficacy 65% over 6 months) [9]. </plain></SENT>
<SENT sid="45" pm="."><plain>In children aged 5 to 17 months in Kenya and Tanzania, proof-of-concept of the RTS,S/AS01E candidate vaccine was recently demonstrated in a trial in which vaccine efficacy against malaria disease was 53%, over an average follow up period of 8 months [10]. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>The trial reported here is one of several age de-escalation, Adjuvant System and schedule selection steps undertaken prior to the conduct of a phase 3 RTS,S trial. </plain></SENT>
<SENT sid="47" pm="."><plain>The schedules under investigation were selected on the basis that they can be integrated into the existing EPI vaccination programme. </plain></SENT>
<SENT sid="48" pm="."><plain>Two or three vaccine doses one month apart (0,1- and 0,1,2-month schedule) could be administered together with two or three doses of DTP respectively, while a third delayed dose could be administered together with measles and yellow fever vaccines at 9 months of age (0,1,7-month schedule). </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="s2"><title><text><SENT sid="49" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>The protocol for this trial [<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</ext-link>: NCT00360230] and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1. </plain></SENT>
</text></p><sec id="s2a"><title><text><SENT sid="51" pm="."><plain>Participants </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>The trial was conducted at two study centres in Ghana: a collaboration between the Kumasi Centre for Collaborative Research (KCCR), Kumasi and the School of Medical Sciences (SMS), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi hosted at the Agogo Presbyterian Hospital and the Kintampo Health Research Centre (KHRC), Ghana Health Service, Ministry of Health, Kintampo. </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>The two centers are about 200 km away from each other. </plain></SENT>
<SENT sid="54" pm="."><plain>The recruitment area for the KCCR/SMS center was the Agogo town, while a more rural population was recruited at KHRC. </plain></SENT>
<SENT sid="55" pm="."><plain>Literacy rates are similar in both populations. </plain></SENT>
<SENT sid="56" pm="."><plain>The main activity is farming. </plain></SENT>
<SENT sid="57" pm="."><plain>The main population groups around KHRC comprise people from the Bono and Mo tribes and there is a large population from northern Ghana that have permanently migrated into Kintampo District. </plain></SENT>
<SENT sid="58" pm="."><plain>The majority of the population around KCCR/SMS is Akan with a small group of migrants from the north of the country. </plain></SENT>
<SENT sid="59" pm="."><plain>The study occurred at the same time in the two sites. </plain></SENT>
<SENT sid="60" pm="."><plain>Although data for health indicators such as HIV prevalence and malaria transmission were not collected as part of the study, the climate and basic health indicators are fairly similar with HIV rates under 4% in both areas. </plain></SENT>
<SENT sid="61" pm="."><plain>Malaria transmission intensity is intense, perennial (269 infectious bites/person/year and a prevalence of malaria parasitaemia among children less than 5 years of about 50% throughout the whole year in Kintampo in 2004) (Owusu-Agyei S., personal communication). </plain></SENT>
<SENT sid="62" pm="."><plain>Impregnated bednets were distributed at screening to potential study participants, regardless of whether children were then enrolled in the trial. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>The protocol was approved by the Food and Drugs Board, Ghana; the Ghana Health Service Ethical Review Committee, Accra, Ghana; the KHRC Institutional Ethics Committee, the KHRC Scientific Review Committee; the Committee on Human Research Protection and Ethics, SMS, KNUST, Kumasi, Ghana; the London School of Hygiene and Tropical Medicine (LSHTM) ethics committee, London, UK and the Western Institutional Review Board, Washington, USA. </plain></SENT>
<SENT sid="64" pm="."><plain>The trial was undertaken according to the International Conference on Harmonization, Good Clinical Practice guidelines and was monitored by GlaxoSmithKline (GSK) Biologicals. </plain></SENT>
<SENT sid="65" pm="."><plain>The study was overseen by a formally constituted Data Safety Monitoring Board (DSMB) operating under a charter. </plain></SENT>
<SENT sid="66" pm="."><plain>The DSMB reviewed safety data from a RTS,S/AS trial in older children [8] prior to authorising the start of this study, and from a subset of children post dose 1 and post dose 2, prior to progression to the next vaccination dose within this trial. </plain></SENT>
<SENT sid="67" pm="."><plain>A Local Safety Monitor was designated at each site whose overall role was to support the clinical investigator and to act as a link between the investigator and the DSMB. </plain></SENT>
</text></p><p><text><SENT sid="68" pm="."><plain>At the KCCR/SMS a register of potentially eligible subjects was made from children attending the immunisation clinics in the town of Agogo. </plain></SENT>
<SENT sid="69" pm="."><plain>KHRC has a Health and Demographic Surveillance System (KHDSS) in place that registers births, deaths and migrations to and from the area. </plain></SENT>
<SENT sid="70" pm="."><plain>The KHDSS was used to compile a list of potentially eligible children from an electronic database held at KHRC. </plain></SENT>
<SENT sid="71" pm="."><plain>In both study sites information was distributed to parents/legally accepted representatives of potential participants through meetings organized in the community, followed by several steps of family and individual based information sessions, with supporting information material. </plain></SENT>
<SENT sid="72" pm="."><plain>Reinforcement and checking of understanding was done with the support of pre-established documents addressing frequently asked questions. </plain></SENT>
<SENT sid="73" pm="."><plain>The whole process happened in the potential participant's own language, in the presence of an impartial literate member of the potential participant's community if parents/legally accepted representatives could not read or write. </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>To qualify for enrolment children had to be free of obvious health problems as established by medical history, clinical examination and laboratory blood markers for safety at screening. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="75" pm="."><plain>Procedures and interventions (Table 1) </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>Access of the study population to general clinical care according to national recommendations was facilitated, in collaboration with the government services. </plain></SENT>
<SENT sid="77" pm="."><plain>Hospital services were open for care on a continuous basis. </plain></SENT>
<SENT sid="78" pm="."><plain>Access to care was facilitated through the reimbursement of transport to the hospital and direct or phone access to field based study staff for the organisation of transport if needed. </plain></SENT>
<SENT sid="79" pm="."><plain>Malaria episodes were treated as recommended by the Ministry of Health of Ghana with oral artesunate and amodiaquine and IV or IM quinine if hospital admission was needed. </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>Both in Kintampo and Agogo, study vaccination sessions were organised in specially dedicated rooms with separated space for vaccine preparation and administration, located in the vicinity of standard EPI clinics, the hospital and research center. </plain></SENT>
<SENT sid="81" pm="."><plain>Recipients of candidate vaccine were administered lyophilised RTS,S reconstituted with 0.5 mL of either AS02D or AS01E Adjuvant Systems. </plain></SENT>
<SENT sid="82" pm="."><plain>Both candidate and control vaccines were administered intramuscularly into the deltoid muscle of the left arm on a 0,1-, 0,1,2- or 0,1,7-month schedule. </plain></SENT>
<SENT sid="83" pm="."><plain>In KHRC, children on the 0,1,2-month schedule received rabies vaccine as a control (Rabipur®; Chiron Behring GmbH). </plain></SENT>
<SENT sid="84" pm="."><plain>In the KCCR/SMS, children on the 0,1,2-month schedule, received the RTS,S/AS02D experimental vaccine as an active comparator. </plain></SENT>
<SENT sid="85" pm="."><plain>Randomisation to each of the other study groups was balanced between the two study sites. </plain></SENT>
<SENT sid="86" pm="."><plain>Vaccinees were observed for 60 minutes following each vaccination. </plain></SENT>
</text></p><p><text><SENT sid="87" pm="."><plain>Volunteers were followed daily for the solicited adverse events (AEs) of pain, swelling, fever (defined as an axillary temperature ≥37.5°C), drowsiness, loss of appetite and irritability/fussiness for a total of 7 days following each vaccination. </plain></SENT>
<SENT sid="88" pm="."><plain>Unsolicited non-serious AEs were collected for 30 days following each dose. </plain></SENT>
<SENT sid="89" pm="."><plain>Serious AEs (SAEs) were recorded throughout the study period. </plain></SENT>
<SENT sid="90" pm="."><plain>Blood draws for safety evaluation and measurement of humoral responses were taken at scheduled time points during the study (see Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0007302-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="91" pm="."><plain>Outline of study design. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0007302-t001-1" xlink:href="pone.0007302.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>Month -1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>Month 0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Days 0+6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>Month 1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>Month 2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>Month 3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>Month 4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>Month 5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Month 6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>Month 7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>Month 8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>Month 9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>Month 10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>Month 19 </plain></SENT>
</text></td></tr></thead><tbody><tr><td colspan="16" align="left" rowspan="1"><text><SENT sid="106" pm="."><plain>Schedule: 0,1-month </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>Vaccination </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>Serology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>CS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>HBs </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>Safety BS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td colspan="16" align="left" rowspan="1"><text><SENT sid="128" pm="."><plain>Schedule: 0,1,2-month </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>Vaccination </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>Serology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>CS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>HBs </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Safety BS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td colspan="16" align="left" rowspan="1"><text><SENT sid="151" pm="."><plain>Schedule: 0,1,7-month </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>Vaccination </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Serology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>CS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>HBs </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>X </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>Safety BS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>X </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="174" pm="."><plain>Double blind (observer blind) phase: screening (Month -1, Month 0, Days 0 and 6) and primary study (Months 1–10). </plain></SENT>
</text></p></fn><fn id="nt102"><label/><p><text><SENT sid="175" pm="."><plain>Single blind phase: extended follow up: Month 19. </plain></SENT>
</text></p></fn><fn id="nt103"><label/><p><text><SENT sid="176" pm="."><plain>Schedule 0,1-month: RTS,S/AS01E (N = 90*), RTS,S/AS02D (N = 90*). </plain></SENT>
</text></p></fn><fn id="nt104"><label/><p><text><SENT sid="177" pm="."><plain>Schedule 0,1,2-month : RTS,S/AS01E (N = 90*), RTS,S/AS02D (N = 45**), Rabies (N = 45***). </plain></SENT>
</text></p></fn><fn id="nt105"><label/><p><text><SENT sid="178" pm="."><plain>Schedule 0,1,7-month: RTS,S/AS01E (N = 90*), RTS,S/AS02D (N = 90*). </plain></SENT>
</text></p></fn><fn id="nt106"><label/><p><text><SENT sid="179" pm="."><plain>FU = follow-up; BS = blood sample; *KHRC = 45, KCCR/SMS = 45; **KCCR/SMS only; ***KHRC only. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s2c"><title><text><SENT sid="180" pm="."><plain>Objectives </plain></SENT>
</text></title><p><text><SENT sid="181" pm="."><plain>The study was a phase II, controlled, randomised, partially-blinded study of 19 months duration of the safety and immunogenicity of two candidate malaria vaccine formulations, RTS,S/AS02D and RTS,S/AS01E, when given according to three different immunisation schedules in 5–17 month old children in Ghana. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="182" pm="."><plain>Endpoints: safety </plain></SENT>
</text></title><p><text><SENT sid="183" pm="."><plain>The primary safety outcome measure was the occurrence of SAEs from the time of first vaccination until 10 months post Dose 1. </plain></SENT>
<SENT sid="184" pm="."><plain>A SAE was defined per protocol as any untoward medical occurrence that was fatal, life-threatening, required hospitalisation, led to disability or incapacity, or was judged by investigator's as being medically important enough to be reported as serious. </plain></SENT>
<SENT sid="185" pm="."><plain>In order to maximize data capture about seizures, all seizures occurring within 30 days of vaccination had to be reported as SAEs. </plain></SENT>
<SENT sid="186" pm="."><plain>Data on seizures occurring within 7 days post vaccination were collected in a standard way according to Brighton collaboration guidelines [11]. </plain></SENT>
<SENT sid="187" pm="."><plain>Secondary safety endpoints included the occurrence of unsolicited AEs after each vaccination over a 30 day follow-up period, solicited local (pain, swelling) and general (measured fever, irritability/fussiness, drowsiness, loss of appetite) reactions over a 7 day period (day of vaccination and 6 subsequent days) following each vaccination. </plain></SENT>
<SENT sid="188" pm="."><plain>Grade 3 general reactions were defined as: fever, an axillary temperature ≥39.0°C; irritability/fussiness, crying that could not be comforted/prevented normal activity; drowsiness that prevented normal activity; loss of appetite, not eating at all. </plain></SENT>
<SENT sid="189" pm="."><plain>Grade 3 solicited local injection site reactions were defined as: pain, cried when limb moved/spontaneously painful; swelling, exceeding 20 mm in diameter. </plain></SENT>
<SENT sid="190" pm="."><plain>Safety laboratory blood assessments for haematological (haemoglobin, white blood cells [WBC], platelets), renal (creatinine), and hepatic (alanine aminotransferase [ALT]) parameters were conducted at specific time points during the study (see Table 1). </plain></SENT>
<SENT sid="191" pm="."><plain>Tertiary endpoints included an assessment of SAEs up to 19 months post Dose 1. </plain></SENT>
</text></p><p><text><SENT sid="192" pm="."><plain>For each AE/SAE, investigators had to assess whether (yes or no) there was a reasonable possibility that the AE may have been caused by the investigational product, using clinical judgment and taking into account the natural history of the underlying diseases, concomitant therapy, other risk factors, the temporal relationship of the event to the investigational product and available information on experimental or marketed products. </plain></SENT>
<SENT sid="193" pm="."><plain>All solicited injection site reactions were considered causally related to vaccination. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="194" pm="."><plain>Endpoints: immunogenicity </plain></SENT>
</text></title><p><text><SENT sid="195" pm="."><plain>Anti-CS and anti-HBs antibodies were assessed prior to vaccination and on several occasions until 19 months post dose 1 (see Table 1). </plain></SENT>
<SENT sid="196" pm="."><plain>Antibody levels against the CS protein tandem repeat epitope were measured by a standard, validated ELISA using theR32LR antigen that contains the sequence [NVDP(NANP)15]2LR [7]. </plain></SENT>
<SENT sid="197" pm="."><plain>Antibody responses against the HBs were quantified by a GSK validated sandwich ELISA. </plain></SENT>
<SENT sid="198" pm="."><plain>Briefly, 96-well microplates were coated with native HBs and after washing and blocking steps, dilutions of serum samples, controls and standard were added to the plate. </plain></SENT>
<SENT sid="199" pm="."><plain>After washing, a recombinant horseradish peroxidase conjugated HBs was added as secondary reagent. </plain></SENT>
<SENT sid="200" pm="."><plain>After a final washing step and a colorimetric reaction with 3,3′,5,5′ tetramethylbenzidine stopped by addition of sulphuric acid, the plates were read in an ELISA reader. </plain></SENT>
<SENT sid="201" pm="."><plain>Titres were calculated using the reference standard curve with a 4 parameter logistic fitting algorithm and expressed in mIU/mL. </plain></SENT>
<SENT sid="202" pm="."><plain>The cut-off was set at 3.3 mIU/mL. </plain></SENT>
</text></p></sec><sec id="s2f"><title><text><SENT sid="203" pm="."><plain>Sample size </plain></SENT>
</text></title><p><text><SENT sid="204" pm="."><plain>For any comparison between two study groups, the study had 80 percent power to detect an approximately 3 fold increase of events, for an event occurring at a frequency of ten percent in the comparator group, by Fisher exact test (alpha 5%). </plain></SENT>
</text></p><p><text><SENT sid="205" pm="."><plain>For the secondary immunogenicity endpoints, anti-CS titres, a sample size of 75 evaluable subjects per group would have 90% power to demonstrate equivalence of the two vaccine regimens under comparison (i.e. x versus y, 95% CI of the GMT ratio x/y is within the range 0.33 to 3.0) at any time point assuming a log standard deviation of 0.9 in both groups, alpha = 0.025. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="206" pm="."><plain>Randomisation and blinding </plain></SENT>
</text></title><p><text><SENT sid="207" pm="."><plain>Subjects were allocated sequentially to treatment numbers in the order that they presented for vaccination. </plain></SENT>
<SENT sid="208" pm="."><plain>Treatment numbers were assigned to vaccines with a randomisation list generated using a standard SAS® (Statistical Analysis System) programme. </plain></SENT>
<SENT sid="209" pm="."><plain>Subjects were allocated randomly (1∶1∶1∶1∶1∶1) to one of six study groups at each study site, each defining which vaccine should be given and by which schedule (0,1-, 0,1,2- or 0,1,7-months). </plain></SENT>
<SENT sid="210" pm="."><plain>For the 0,1,2-month schedule this meant RTS,S/AS01E or rabies vaccine at KHRC and RTS,S/AS01E or RTS,S/AS02D at KCCR/SMS. </plain></SENT>
<SENT sid="211" pm="."><plain>For the other schedules at both study sites, this meant either RTS,S/AS01E or RTS,S/AS02D. </plain></SENT>
</text></p><p><text><SENT sid="212" pm="."><plain>During the primary phase of the study, i.e. up to month 10, the study was partially blinded, whereby investigators involved in endpoint evaluation and parents/guardians were blinded to the vaccine administered, but not to the schedule. </plain></SENT>
<SENT sid="213" pm="."><plain>The vaccine administration occurred in a separate room in the presence of a vaccination team that was not involved in any other part in the study, as described in detailed standard procedures. </plain></SENT>
<SENT sid="214" pm="."><plain>From months 10 to 19, during the extended follow-up period, the study was single-blind as parents/guardians remained blind to the study vaccine. </plain></SENT>
</text></p></sec><sec id="s2h"><title><text><SENT sid="215" pm="."><plain>Statistical methods </plain></SENT>
</text></title><p><text><SENT sid="216" pm="."><plain>Analysis was carried out according to a DSMB approved report and analysis plan established before unblinding of trial data. </plain></SENT>
</text></p><sec id="s2h1"><title><text><SENT sid="217" pm="."><plain>Safety </plain></SENT>
</text></title><p><text><SENT sid="218" pm="."><plain>The proportion of subjects with a SAE, classified by the MedDRA preferred term level, reported from study start until study conclusion was tabulated with exact 95% confidence interval (CI). </plain></SENT>
<SENT sid="219" pm="."><plain>The percentage of subjects with at least one solicited local and general AE reported within 7 days post each vaccination was also tabulated, with exact 95% CI. </plain></SENT>
<SENT sid="220" pm="."><plain>The proportion of subjects who reported an unsolicited AE within 30 days post each vaccination, classified by the MedDRA preferred term level, was tabulated with exact 95% CI. </plain></SENT>
<SENT sid="221" pm="."><plain>Similar tables were generated for Grade 3 solicited and unsolicited AEs and for the relationship of the event to vaccination; per protocol, all solicited local AEs were considered to be related to vaccination. </plain></SENT>
<SENT sid="222" pm="."><plain>Biochemistry (ALT and creatinine) and haematology (haemoglobin, WBC, platelets) values outside of the reference ranges were described up to 19 months post Dose 1; frequency distribution of results by predefined toxicity grades were tabulated by group. </plain></SENT>
</text></p></sec><sec id="s2h2"><title><text><SENT sid="223" pm="."><plain>Immunogenicity </plain></SENT>
</text></title><p><text><SENT sid="224" pm="."><plain>The percentage of subjects seropositive for anti-CS antibody (anti-CS antibody titres ≥0.5 EU/mL) with 95% CI was determined at each blood sampling time point (Table 1). </plain></SENT>
<SENT sid="225" pm="."><plain>Antibody titres were summarised by GMT with 95% CI. </plain></SENT>
<SENT sid="226" pm="."><plain>The area under the curve (AUC) of anti-CS responses over time was estimated over the vaccination period to month 7 (AUC7) and over the whole study duration to month 19 (AUC19), by trapezoidal rule using the consecutive blood samples. </plain></SENT>
<SENT sid="227" pm="."><plain>Month 2 data from the 0,1-month schedule was used to estimate the AUC for the 0,1,7-month schedule. </plain></SENT>
<SENT sid="228" pm="."><plain>Standardised AUC (sAUC), calculated by dividing AUC by follow-up time, was also calculated. </plain></SENT>
</text></p><p><text><SENT sid="229" pm="."><plain>The seroprotective level for anti-HBs antibody was ≥10 mIU/mL. </plain></SENT>
<SENT sid="230" pm="."><plain>The percentage of subjects with seroprotective levels of anti-HBs with 95% CI was determined at each blood sampling time point (Table 1). </plain></SENT>
<SENT sid="231" pm="."><plain>Antibody titres were summarised by GMT with 95% CI at each blood sampling time point. </plain></SENT>
</text></p></sec></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="232" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="233" pm="."><plain>Participant flow </plain></SENT>
</text></title><p><text><SENT sid="234" pm="."><plain>In total, 756 subjects were screened of whom 540 were enrolled into the study and evaluated for safety; 90 in each of the RTS,S/AS02D (0,1- and 0,1,7-month) and RTS,S/AS01E (0,1-, 0,1,2- and 0,1,7-month) groups and 45 in each of the RTS,S/AS02D (0,1,2-month) and rabies vaccine groups (Figure 1). </plain></SENT>
<SENT sid="235" pm="."><plain>531 subjects received all vaccine doses as scheduled and 521 were evaluable for the ATP cohort for immunogenicity. </plain></SENT>
<SENT sid="236" pm="."><plain>Twenty-five subjects (4.6%) were prematurely withdrawn from the study, predominantly due to migration from the study area (15 subjects). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0007302-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="237" pm="."><plain>CONSORT diagram for study participants. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0007302.g001"/></fig></SecTag><p><text><SENT sid="238" pm="."><plain>The first subject was enrolled in the study on 30 August 2006 and the last study visit was made on 30 May 2008. </plain></SENT>
</text></p></sec><sec id="s3b"><title><text><SENT sid="239" pm="."><plain>Baseline data </plain></SENT>
</text></title><p><text><SENT sid="240" pm="."><plain>For the total vaccinated cohort and the ATP cohort for immunogenicity the mean age at study entry was 10.7 months (standard deviation [SD] 3.5). </plain></SENT>
<SENT sid="241" pm="."><plain>Each group was balanced for gender and age, overall and by study center (Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0007302-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="242" pm="."><plain>Summary of demographic characteristics by site and overall (Total vaccinated cohort). </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0007302-t002-2" xlink:href="pone.0007302.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1"><text><SENT sid="243" pm="."><plain>KHRC </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="244" pm="."><plain>KCCR </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="245" pm="."><plain>Total </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Group </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>Age (months) mean±SD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Gender F∶M (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Age for weight z-score mean±SD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Age (months) mean±SD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>Gender F∶M (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Age for weight z-score mean±SD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Age (months) mean±SD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Gender F∶M (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Age for weight z-score mean±SD </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>RTS,S/AS02D (0,1-month) N = 90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>10.7±3.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>42∶58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>−1.0±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>10.3±3.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>49∶51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>−1.2±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>10.5±3.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>46∶54 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>−1.1±1.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>RTS,S/AS01E (0,1-month) N = 90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>10.7±3.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>38∶62 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>−1.0±1.0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>10.1±3.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>56∶44 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>−1.1±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>10.4±3.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>47∶53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>−1.1±1.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>RTS,S/AS02D (0,1,2-month) N = 45 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>11.2±3.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>51∶49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>−1.5±1.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>11.2±3.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>51∶49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>−1.5±1.2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>RTS,S/AS01E (0,1,2-month) N = 90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>10.8±3.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>42∶58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>−1.0±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>11.0±3.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>47∶53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>−1.3±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>10.9±3.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>44∶56 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>−1.1±1.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>RTS,S/AS02D (0,1,7-month) N = 90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>11.2±3.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>51∶49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>−1.0±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>9.7±3.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>47∶53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>−1.2±1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>10.4±3.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>49∶51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>−1.1±1.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>RTS,S/AS01E (0,1,7-month) N = 90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>11.4±3.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>62∶38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>−0.7±1.0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>10.0±3.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>44∶56 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>−1.1±1.0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>10.7±3.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>53∶47 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>−0.9±1.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>Rabies (0,1,2-month) N = 45 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>10.9±3.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>60∶40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>−0.8±1.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>10.9±3.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>60∶40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>−0.8±1.2 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label/><p><text><SENT sid="326" pm="."><plain>KHRC = Kintampo Health Research Centre; KCCR = Kumasi Centre for Collaborative Research, Agogo. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3c"><title><text><SENT sid="327" pm="."><plain>Safety </plain></SENT>
</text></title><sec id="s3c1"><title><text><SENT sid="328" pm="."><plain>Serious adverse events </plain></SENT>
</text></title><p><text><SENT sid="329" pm="."><plain>11.1% [5.5–19.5] and 20.0% [12.3–29.8] of the subjects in the RTS,S/AS02D (0,1-month) group, 21.1% [13.2–31.0] and 25.6% [16.9–35.8] in the RTS,S/AS01E (0,1-month) group, 11.1% [3.7–24.1] and 24.4% [12.9–39.5] in the RTS,S/AS02D (0,1,2-month) group, 14.4% [7.9–23.4] and 24.4% [16.0–34.6] in the RTS,S/AS01E (0,1,2-month) group, 18.9% [11.4–28.5] and 26.7% [17.9–37.0] in the RTS,S/AS02D (0,1,7-month) group, 15.6% [8.8–24.7] and 18.9% [11.4–28.5] in the RTS,S/AS01E (0,1,7-month) group, and 13.3% [6.1–26.8] and 15.6% [6.5–29.5] in the Rabies (0,1,2-month) group reported at least one SAE from day of first vaccination to Month 10 (primary endpoint) and Month 19, respectively. </plain></SENT>
<SENT sid="330" pm="."><plain>No apparent imbalance between study groups in the occurrence of SAEs was observed, which was also true for the entire study duration, to Month 19 (not shown). </plain></SENT>
</text></p><p><text><SENT sid="331" pm="."><plain>Four subjects died during the trial; one child from the RTS,S/AS01E 0,1,7-month schedule group died at home 7 days after having received the second experimental vaccine dose. </plain></SENT>
<SENT sid="332" pm="."><plain>A diagnosis of bronchopneumonia was made by verbal autopsy. </plain></SENT>
<SENT sid="333" pm="."><plain>One child from the rabies vaccine group died in hospital from severe malaria with severe anaemia and sepsis 7 months after the last vaccine dose. </plain></SENT>
<SENT sid="334" pm="."><plain>One child from the RTS,S/AS01E 0,1-month schedule group died in hospital of cerebral malaria 17 months after the last vaccine dose. </plain></SENT>
<SENT sid="335" pm="."><plain>Another child died in hospital of severe malaria, severe anaemia and convulsions, 18 months after enrolment. </plain></SENT>
<SENT sid="336" pm="."><plain>He was due to receive RTS,S/AS01E (0,1,7-month schedule) but the first vaccination attempt failed, there was spillage of the attributed vaccine dose, and he received only a negligible amount of vaccine. </plain></SENT>
<SENT sid="337" pm="."><plain>After this failed attempt, he was not further vaccinated. </plain></SENT>
<SENT sid="338" pm="."><plain>None of the fatal SAEs were considered to be related to vaccination. </plain></SENT>
</text></p><p><text><SENT sid="339" pm="."><plain>One SAE was considered to be related to vaccination: an 18 month old boy experienced a simple febrile seizure 14 hours after dose 3 of RTS,S/AS01E at home. </plain></SENT>
<SENT sid="340" pm="."><plain>Earlier on the same day, fever had been recorded as part of the routine reactogenicity monitoring. </plain></SENT>
<SENT sid="341" pm="."><plain>A few hours after the episode of convulsion he was seen at the district hospital, and found to be well. </plain></SENT>
<SENT sid="342" pm="."><plain>Physical examination and laboratory assessment did not show any evidence of infectious disease. </plain></SENT>
<SENT sid="343" pm="."><plain>He was treated with paracetamol only. </plain></SENT>
<SENT sid="344" pm="."><plain>He was kept for observation for 2 days and went home thereafter. </plain></SENT>
</text></p><p><text><SENT sid="345" pm="."><plain>Two children in the study were diagnosed with intussusception. </plain></SENT>
<SENT sid="346" pm="."><plain>The first case was a 14 month old boy who presented on the day following the first RTS,S/AS01E vaccination (0,1-month schedule group) with mucoid bloody diarrhoea, vomiting and fever, and was treated with oral antibiotics. </plain></SENT>
<SENT sid="347" pm="."><plain>Five days later he returned with a mass in his epigastrium. </plain></SENT>
<SENT sid="348" pm="."><plain>The second case was a 7 month old boy who presented fifteen days after first RTS,S/AS02D vaccination (0,1,7-month schedule group) with a 1 day history of bloody mucoid stool, abdominal pain and a mass in the epigastrium. </plain></SENT>
<SENT sid="349" pm="."><plain>Both children were referred to the tertiary level university hospital where the diagnosis of intussusception was confirmed and treated surgically. </plain></SENT>
<SENT sid="350" pm="."><plain>Both children recovered fully. </plain></SENT>
<SENT sid="351" pm="."><plain>On the basis of the absence of obvious pathogenic explanation for these vaccine components being causative of intussusceptions, as well as the fact that they occurred at different time intervals after vaccination and following vaccination with different vaccine formulations, the investigators considered the intussusceptions not to be related to vaccination. </plain></SENT>
<SENT sid="352" pm="."><plain>The DSMB concurred with this assessment. </plain></SENT>
</text></p></sec><sec id="s3c2"><title><text><SENT sid="353" pm="."><plain>Non-serious adverse events and reactogenicity </plain></SENT>
</text></title><p><text><SENT sid="354" pm="."><plain>For each RTS,S vaccine formulation, reactogenicity seen after the first two doses in the three vaccine schedule groups was similar. </plain></SENT>
<SENT sid="355" pm="."><plain>Therefore the description of reactogenicity focuses on the data from the 0,1,2- and 0,1,7-month schedules and data from the 0,1-month schedule groups is not presented here. </plain></SENT>
</text></p><p><text><SENT sid="356" pm="."><plain>Pain at the injection site was the most frequently reported solicited local symptom. </plain></SENT>
<SENT sid="357" pm="."><plain>It was reported with a higher frequency in the RTS,S/AS02D compared to the RTS,S/AS01E group (overall/dose: 0,1,2-month schedule, 43.6% vs 29.6% [rabies 20.1%]); 0,1,7-month schedule, 53.2% vs 44.1%, respectively). </plain></SENT>
<SENT sid="358" pm="."><plain>Although Grade 3 pain occurred with a low incidence, there was a trend towards a higher frequency of Grade 3 pain in the RTS,S/AS02D compared to the RTS,S/AS01E group (Figure 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0007302-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="359" pm="."><plain>Percentage of solicited events post dose 1, 2 and 3 (Total Vaccinated Cohort). </plain></SENT>
</text></title><p><text><SENT sid="360" pm="."><plain>Yellow = RTS,S/AS02D; Green = RTS,S/AS01E; Grey = Rabies vaccine; Orange = Grade 3 Bars represent 95% confidence intervals. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0007302.g002"/></fig></SecTag><p><text><SENT sid="361" pm="."><plain>A similar pattern was observed for swelling (overall/dose: 0,1,2-month, RTS,S/AS02D 35.3% vs RTS,S/AS01E 12.6% [rabies 2.2%]; 0,1,7-month, RTS,S/AS02D 18.4% vs RTS,S/AS01E 14.1%). </plain></SENT>
<SENT sid="362" pm="."><plain>Grade 3 swelling events were infrequent (Figure 2). </plain></SENT>
</text></p><p><text><SENT sid="363" pm="."><plain>Fever was the most frequently reported solicited general symptom, occurring with a similar incidence in both the RTS,S/AS02D and RTS,S/AS01E vaccine groups and in both the 0,1,2-month (overall/dose: 39.1% vs 35.9%, respectively [rabies 11.2%]) and the 0,1,7-month (47.9% vs 46.8%, respectively) schedules (Figure 2). </plain></SENT>
<SENT sid="364" pm="."><plain>Grade 3 fever events were reported in the 0,1,2-month group following 0.8% and 1.9% of RTS,S/AS02D and RTS,S/AS01E doses respectively (rabies 1.5%), and in the 0,1,7-month group following 5.6% and 2.7% of RTS,S/AS02D and RTS,S/AS01E doses, respectively. </plain></SENT>
</text></p><p><text><SENT sid="365" pm="."><plain>Unsolicited non-serious AEs were reported by a similar proportion of subjects who received RTS,S/AS02D or RTS,S/AS01E in the 0,1,2-month (53.4% vs 57.4% [rabies 59.7%]) and in the 0,1,7-month (93.3% vs 94.4%) groups. </plain></SENT>
<SENT sid="366" pm="."><plain>There was no trend in non-serious AEs Graded 3 for intensity across groups (0,1,2-month, 2.2% RTS,S/AS02D vs 7.8% RTS,S/AS01E [rabies 4.4%]; 0,1,7-month, 10.0% RTS,S/AS02D vs 7.8% RTS,S/AS01E). </plain></SENT>
<SENT sid="367" pm="."><plain>There were no non-serious AEs estimated by the investigators to be related to vaccination. </plain></SENT>
</text></p><p><text><SENT sid="368" pm="."><plain>Haematology (haemoglobin, WBC, platelets) and biochemistry (ALT, creatinine) values outside the normal range were infrequent. </plain></SENT>
<SENT sid="369" pm="."><plain>Three subjects had values graded 3. </plain></SENT>
<SENT sid="370" pm="."><plain>One subject in the RTS,S/AS02D (0,1,7-month) group had elevated ALT at month 7 (416 U/mL). </plain></SENT>
<SENT sid="371" pm="."><plain>The child was found to be well, followed up clinically and the ALT level was normal at the next visit. </plain></SENT>
<SENT sid="372" pm="."><plain>One subject in the RTS,S/AS02D (0,1,7-month) group had elevated ALT at month 7 (353 U/mL). </plain></SENT>
<SENT sid="373" pm="."><plain>He had a concomitant upper respiratory tract infection and was otherwise well. </plain></SENT>
<SENT sid="374" pm="."><plain>He was followed up clinically and the ALT level was normal at the next visit. </plain></SENT>
<SENT sid="375" pm="."><plain>One subject in the RTS,S/AS01E (0,1,7-month) group had raised creatinine at month 8 (225 mg/dL). </plain></SENT>
<SENT sid="376" pm="."><plain>He was found to be well clinically, and at the next visit the creatinine concentration had reduced (67.1 mg/dL). </plain></SENT>
</text></p></sec></sec><sec id="s3d"><title><text><SENT sid="377" pm="."><plain>Immunogenicity </plain></SENT>
</text></title><p><text><SENT sid="378" pm="."><plain>All subjects were seropositive for anti-CS antibodies following 2 doses of either RTS,S/AS01E or RTS,S/AS02D; low, background levels of anti-CS antibodies were found in rabies-vaccinated subjects. </plain></SENT>
</text></p><p><text><SENT sid="379" pm="."><plain>In general, the levels of antibody responses in Kintampo were slightly higher than those in Agogo. </plain></SENT>
<SENT sid="380" pm="."><plain>For example, in the 0,1,7-month schedule groups, peak (month 8) anti-CS GMT following vaccination with RTS,S/AS02D was 230 (95% CI 171, 309) in Agogo and 316 (95% CI 228, 437) in Kintampo, and following vaccination with RTS,S/AS01E was 363 (95% CI 274, 481) in Agogo and 383 (95% CI 301, 488) in Kintampo (other data not shown). </plain></SENT>
<SENT sid="381" pm="."><plain>This trend was also observed for anti-hepatitis B antibodies (data not shown). </plain></SENT>
<SENT sid="382" pm="."><plain>The general conclusions from analysis of site-specific results (data not shown) were similar to those following review of pooled data from the two research centres as presented here. </plain></SENT>
</text></p><p><text><SENT sid="383" pm="."><plain>Within each vaccination schedule group, the RTS,S/AS01E formulation consistently yielded higher peak anti-CS responses as compared to RTS,S/AS02D. </plain></SENT>
<SENT sid="384" pm="."><plain>The highest anti-CS GMTs were seen with the 0,1,2-month schedule at month 3 (632 EU/mL [95% CI 554, 720]). </plain></SENT>
<SENT sid="385" pm="."><plain>With the same schedule, the RTS,S/AS02D formulation induced anti-CS GMTs of 367 EU/mL (95% CI 293, 459). </plain></SENT>
<SENT sid="386" pm="."><plain>With the 0,1,7-month schedule at month 8, anti-CS GMTs were 373 EU/mL (95% CI 311, 447) for the RTS,S/AS01E formulation and 272 EU/mL (95% CI 219, 339) for the RTS,S/AS02D formulation. </plain></SENT>
<SENT sid="387" pm="."><plain>With the 0,1-month schedule at month 2, anti-CS GMTs were 483 EU/mL (95% CI 395, 591) for the RTS,S/AS01E formulation and 318 EU/mL (95% CI 269, 377) for the RTS,S/AS02D formulation. </plain></SENT>
</text></p><p><text><SENT sid="388" pm="."><plain>At month 7, subjects having received two vaccine doses (i.e. the 0,1-month schedule) had lower anti-CS GMTs (AS02D: 35 EU/mL [95% CI: 26, 46]; AS01E: 53 EU/mL [95% CI: 41, 68]) than subjects having received 3 vaccine doses (0,1,2-month schedule) (AS02D: 78 EU/mL [95% CI: 58, 106]; AS01E: 162 EU/mL [95% CI: 134, 196]). </plain></SENT>
<SENT sid="389" pm="."><plain>This trend was also observed at month 19. </plain></SENT>
</text></p><p><text><SENT sid="390" pm="."><plain>At month 19, similar anti-CS levels were found in both RTS,S/AS01E schedule groups (0,1,7-month schedule 51 EU/mL [95% CI: 40, 66], 0,1,2-month schedule 46 EU/mL [95% CI: 37, 57]). </plain></SENT>
<SENT sid="391" pm="."><plain>In the RTS,S/AS02D groups, the 0,1,7-month schedule induced higher month 19 anti-CS titres as compared to the 0,1,2-month schedule (44 EU/mL [95% CI: 33, 58] vs 20 EU/mL [95%CI: 14, 29] respectively) (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0007302-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="392" pm="."><plain>Anti-CS GMTs (EU/mL) responses over time (0,1,2- and 0,1,7-month schedules; ATP Cohort for Immunogenicity). </plain></SENT>
</text></title><p><text><SENT sid="393" pm="."><plain>Note : There was no month 2 blood sample in the 0,1,7-month schedule group. </plain></SENT>
<SENT sid="394" pm="."><plain>Month 2 data from the 0,1-month schedule group was used instead. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0007302.g003"/></fig></SecTag><p><text><SENT sid="395" pm="."><plain>For all schedules, AUC was consistently higher for the RTS,S/AS01E groups compared to the RTS,S/AS02D groups (Table 3). </plain></SENT>
<SENT sid="396" pm="."><plain>For the RTS,S/AS01E formulation, anti-CS sAUC19 over the whole study duration were comparable for the 0,1,2- and 0,1,7-month schedules and higher than for the 0,1-month schedule; the same trend, but less pronounced was observed for the RTS,S/AS02D formulation. </plain></SENT>
<SENT sid="397" pm="."><plain>Anti-CS responses during the vaccination period (sAUC7) were high for all study groups with an apparent trend towards the highest values with the 0,1,2-month schedule in the RTS,S/AS01E group. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0007302-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007302.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="398" pm="."><plain>GMTs and sAUC for anti-CS antibodies and GMTs for anti-HBs antibodies (ATP Cohort for Immunogenicity). </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0007302-t003-3" xlink:href="pone.0007302.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Schedule </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="400" pm="."><plain>0,1-month </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="401" pm="."><plain>0,1,2-month </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="402" pm="."><plain>0,1,7-month </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>RTS,S/AS02D </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>RTS,S/AS01E </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>RTS,S/AS02D </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>RTS,S/AS01E </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>Rabies </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>RTS,S/AS02D </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>RTS,S/AS01E </plain></SENT>
</text></td></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="410" pm="."><plain>Anti-CS (EU/mL); GMTS [95% CI] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>SCR </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>0.3 [0.2, 0.3] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>0.3 [0.3, 0.3] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>M2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>318 [269, 377] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>483 [395, 591] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>M3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>367 [293, 459] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>632 [554, 720] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>0.4 [0.3, 0.6] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>M7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>35 [26, 46] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>53 [41, 68] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>78 [58, 106] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>162 [134, 196] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>26 [20, 34] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>51 [40, 64] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>M8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>272 [219, 339] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>373 [311, 447] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>M10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>20 [15, 27] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>32 [23, 40] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>43 [32, 60] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>102 [83, 125] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>0.3 [0.3, 0.4] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>120 [92, 156] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>167 [140, 198] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>M19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>10 [7], [14] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>15 [11], [21] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>20 [14, 29] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>46 [37, 57] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>0.5 [0.3, 0.7] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>44 [33, 58] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>51 [40, 66] </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="462" pm="."><plain>Anti-CS sAUC; Gmean [95% CI] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>sAUC7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>181 [151, 218] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>269 [218, 332] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>225 [182, 279] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>371 [324, 426] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>166* [139, 198] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>249* [204, 302] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>sAUC19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>83 [69, 101] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>124 [101, 153] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>113 [90, 143] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>200 [173, 232] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>141 [116, 173] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>203 [172, 240] </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="479" pm="."><plain>Anti-HBs (mIU/mL); GMTS [95% CI] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>SCR </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>101 [68, 149] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>108 [74, 158] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>109 [61, 195] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>82 [61, 111] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>108 [64, 183] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>88 [61, 128] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>90 [61, 133] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>M2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>17043 [10467, 27751] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>15107 [9508, 24001] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>M3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>30000 [18799, 47874] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>34935 [25178, 48474] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>122 [63, 235] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>M8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>96754 [72062, 129908] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>103225 [83035, 128324] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>M19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>3510 [2398, 5137] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>4478 [3155, 6357] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>5112 [3350, 7803] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>7106 [5161, 9784] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>114 [58, 227] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>17191 [12529, 23589] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>13386 [9661, 18548] </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><label/><p><text><SENT sid="506" pm="."><plain>SCR = screening visit; sAUC 7/19 = standardised area under the curve over the vaccination period to Month 7/Month 19. </plain></SENT>
</text></p></fn><fn id="nt109"><label>*</label><p><text><SENT sid="507" pm="."><plain>sAUC7 here represents a period during which only the first two vaccine doses were given, as for the 0,1-month schedule. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="508" pm="."><plain>All the subjects in this study had previously received hepatitis B vaccination as part of their national EPI, with at least 84% of subjects having seroprotective levels of anti-HBs antibodies at screening. </plain></SENT>
<SENT sid="509" pm="."><plain>All children who received at least 2 RTS,S vaccine doses had seroprotective levels of anti-HBs antibodies, except one subject in the RTS,S/AS02D 0,1-month schedule group. </plain></SENT>
<SENT sid="510" pm="."><plain>Seropositivity rates in the rabies group were 84%, illustrating a persistence of the response induced by the prior hepatitis B EPI vaccination. </plain></SENT>
</text></p><p><text><SENT sid="511" pm="."><plain>Very high levels of anti-HBs GMTs were seen in subjects vaccinated with RTS,S vaccines; no significant difference was seen between RTS,S/AS01E and RTS,S/AS02D formulations within vaccine schedules (Table 3). </plain></SENT>
<SENT sid="512" pm="."><plain>One month post last dose and at month 19, the 0,1,7-month schedule generated the highest anti-HBs GMTs. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="513" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="514" pm="."><plain>The development of a safe, effective malaria vaccine accessible to those who need it most is a critical global public health priority [12]. </plain></SENT>
<SENT sid="515" pm="."><plain>Evidence of immunogenicity, efficacy and a favourable safety profile of the RTS,S/AS02 candidate malaria vaccine has been demonstrated in adults [13]–[16] and subsequently in children and infants [7], [17]–[21]. </plain></SENT>
</text></p><p><text><SENT sid="516" pm="."><plain>Pre-clinical data suggested that the liposomal Adjuvant System formulation RTS,S/AS01 induces stronger immune responses as compared to RTS,S/AS02 [3]. </plain></SENT>
<SENT sid="517" pm="."><plain>In healthy human adults RTS,S/AS01, as compared to RTS,S/AS02, induced higher levels of anti-CS antibodies and CS-specific CD4 positive helper T cells expressing markers of activation and/or effector cytokines, and a trend towards higher protection against infection following experimental sporozoite challenge [4]. </plain></SENT>
<SENT sid="518" pm="."><plain>The good safety profile and high immunogenicity of the RTS,S/AS01 formulation was confirmed in malaria-exposed adults in Kenya [5]. </plain></SENT>
</text></p><p><text><SENT sid="519" pm="."><plain>Recently completed trials have compared the paediatric formulations of the candidate vaccines RTS,S/AS02D and RTS,S/AS01E in children aged 18 months to 4 years from Gabon [8], assessed RTS,S/AS02D when coadministered with EPI antigens in infants from Tanzania [9] and established proof-of-concept of RTS,S/AS01E in children aged 5 to 17 months from Kenya and Tanzania [10]. </plain></SENT>
<SENT sid="520" pm="."><plain>The trial reported here is the next in a series of age de-escalation steps towards the EPI age range, contributing to adjuvant and schedule selection. </plain></SENT>
<SENT sid="521" pm="."><plain>This study is the first comparative assessment of both candidate vaccines in young children aged 5 to 17 months and assessed three different vaccination schedules (0,1-, 0,1,2- and 0,1,7-months). </plain></SENT>
</text></p><p><text><SENT sid="522" pm="."><plain>Overall, both the RTS,S/AS02D and RTS,S/AS01E formulations were shown to have a good safety profile and were well tolerated. </plain></SENT>
<SENT sid="523" pm="."><plain>One subject experienced an episode of simple febrile seizure considered to be related to vaccination following the third dose of RTS,S/AS01E at month 7. </plain></SENT>
<SENT sid="524" pm="."><plain>In the RTS,S program to date 5315 doses of RTS,S/AS02 and 3149 doses of RTS,S/AS01 have been administered to 1864 and 1145 children under 6 years of age, respectively. </plain></SENT>
<SENT sid="525" pm="."><plain>Out of these one other case of simple febrile seizure related to vaccination has occurred [10]. </plain></SENT>
<SENT sid="526" pm="."><plain>Post vaccination febrile seizures are a well described complication of vaccine-related fever [11]. </plain></SENT>
<SENT sid="527" pm="."><plain>In the great majority of the cases, such as in these that have occurred in the RTS,S programme, it is benign, and resolves without sequelae. </plain></SENT>
<SENT sid="528" pm="."><plain>Two cases of intussusception (one in a RTS,S/AS02D vaccinated child, one in a RTS,S/AS01E vaccinated child) were reported in this study. </plain></SENT>
<SENT sid="529" pm="."><plain>Intussusception is a condition known to occur in this age group, including in Ghana, although precise incidence rates are unknown [22]. </plain></SENT>
<SENT sid="530" pm="."><plain>No other case of intussusception has been described in the RTS,S program to date. </plain></SENT>
</text></p><p><text><SENT sid="531" pm="."><plain>The analysis of reactogenicity data indicated that although recipients of the malaria vaccine candidates reported more local and general symptoms than recipients of the rabies vaccine, grade 3 reactions were infrequent. </plain></SENT>
<SENT sid="532" pm="."><plain>A trend towards less local reactogenicity in recipients of the RTS,S/AS01E vaccine formulation as compared to RTS,S/AS02D recipients was found. </plain></SENT>
</text></p><p><text><SENT sid="533" pm="."><plain>In a previous study in children aged 18 months to 4 years from Gabon, both candidate vaccines were shown to have a good safety profile and to be well tolerated [8]. </plain></SENT>
<SENT sid="534" pm="."><plain>In the study in Gabon, an increase in solicited local symptoms of pain and swelling at the injection site with subsequent doses of either vaccine was observed; this was not seen in this study. </plain></SENT>
<SENT sid="535" pm="."><plain>More recently, the RTS,S/AS02D formulation coadministered to infants with other routinely delivered EPI immunisations, and RTS,S/AS01E administered to children aged 5 to 17 months from Kenya and Tanzania, had favourable safety profiles [9], [10]. </plain></SENT>
</text></p><p><text><SENT sid="536" pm="."><plain>Both candidate vaccines were highly immunogenic for anti-CS antibodies. </plain></SENT>
<SENT sid="537" pm="."><plain>Following two doses of either RTS,S/AS01E or RTS,S/AS02D, all subjects had seropositive levels of anti-CS antibodies. </plain></SENT>
<SENT sid="538" pm="."><plain>The peak anti-CS titres were higher than those observed in previous studies in children with RTS,S candidate vaccines [6], [7], [8], [20], [21]. </plain></SENT>
<SENT sid="539" pm="."><plain>This may be related to the fact that in this study all children had been previously immunised against hepatitis B. </plain></SENT>
<SENT sid="540" pm="."><plain>Indeed, it has previously been observed that prior HBV vaccination appears to promote the immune response to both HBs and CS antigen components of RTS,S/AS02 and RTS,S/AS01 [8]. </plain></SENT>
<SENT sid="541" pm="."><plain>Such high anti-CS and –HBs titres were also observed following administration of RTS,S/AS01E to young children previously vaccinated with hepatitis B vaccine in another study [10]. </plain></SENT>
</text></p><p><text><SENT sid="542" pm="."><plain>The antibody response to the CS protein is believed to be an important component or marker of protective immunity although, to date, no protective threshold of CS antibody response has been determined. </plain></SENT>
<SENT sid="543" pm="."><plain>Future studies with the RTS,S candidate vaccines will investigate the priming effect of a neonatal dose of hepatitis B vaccine on the evolution of CS titres induced by the malaria vaccine. </plain></SENT>
</text></p><p><text><SENT sid="544" pm="."><plain>Recipients of RTS,S/AS01E consistently had higher peak anti-CS responses compared to recipients of RTS,S/AS02D, irrespective of vaccination schedule. </plain></SENT>
<SENT sid="545" pm="."><plain>Although responses in subjects who received just 2 doses (i.e. 0,1-month schedule) were high, the decline from peak GMTs was more important than in subjects on a 3 dose regimen. </plain></SENT>
<SENT sid="546" pm="."><plain>Anti-CS titres were higher at month 10 in children on the 0,1,7-month schedule as compared to the 0,1,2-month schedule, for both RTS,S vaccine groups. </plain></SENT>
<SENT sid="547" pm="."><plain>At month 19 this was still apparent in children vaccinated with RTS,S/AS02D but in children vaccinated with RTS,S/AS01E they were similar. </plain></SENT>
</text></p><p><text><SENT sid="548" pm="."><plain>In an attempt to estimate antibody response over the whole timeframe of the study, while acknowledging the variation in the responses over time, AUCs standardised over time were evaluated. </plain></SENT>
<SENT sid="549" pm="."><plain>The evaluation over the whole study duration (AUC19) showed that mean responses with the RTS,S/AS01E formulation were similar for both the 0,1,2- and 0,1,7-month schedules, which were higher than those seen with the two doses schedule. </plain></SENT>
<SENT sid="550" pm="."><plain>Although the anti-CS response following two doses was high, the peak, AUC7 and AUC19 in the 0,1,2-month schedules were higher. </plain></SENT>
<SENT sid="551" pm="."><plain>A two doses schedule is therefore probably not optimal. </plain></SENT>
</text></p><p><text><SENT sid="552" pm="."><plain>Peak responses for anti-CS GMTs were observed in the 0,1,2-month schedules, which was an unexpected result as, in line with licensed Hepatitis B vaccine schedules, trials with a hepatitis B vaccine have shown that increasing the interval between the second and third dose enhances humoral response [23], [24]. </plain></SENT>
<SENT sid="553" pm="."><plain>Indeed, the highest peak responses for anti-HBs GMTs were observed in the 0,1,7-month schedules as compared to the 0,1,2-month schedule when considering the peak (one month post last dose) responses. </plain></SENT>
<SENT sid="554" pm="."><plain>It is not clear why the delayed third dose is associated with a marked increase in HBs response but not CS response and will need to be investigated further in delayed booster studies. </plain></SENT>
</text></p><p><text><SENT sid="555" pm="."><plain>This study confirmed the previously demonstrated high immunogenicity of RTS,S based vaccines for anti-HBs antibodies, and that this is true also in subjects primed with hepatitis B vaccine. </plain></SENT>
</text></p><p><text><SENT sid="556" pm="."><plain>In two similar Ghanaian populations, antibody responses were high though there was some variability between the two centers. </plain></SENT>
<SENT sid="557" pm="."><plain>Slightly higher antibody levels were found in KHRC participants, as compared to KCCR/SMS participants. </plain></SENT>
<SENT sid="558" pm="."><plain>Some variability magnitude of anti CS response between centers has previously been observed and the precise source of this heterogeneity is unclear. </plain></SENT>
<SENT sid="559" pm="."><plain>Future multicenter Phase 3 RTS,S studies will further characterize heterogeneity in vaccine immunogenicity and efficacy in different geographical locations. </plain></SENT>
</text></p><p><text><SENT sid="560" pm="."><plain>This trial demonstrated that both formulations of the candidate malaria vaccines, RTS,S/AS01E and RTS,S/AS02D, were well tolerated and highly immunogenic for anti-CS and anti-HBs antibodies in young children aged 5–17 months living in a malaria-endemic area. </plain></SENT>
<SENT sid="561" pm="."><plain>RTS,S based vaccines were well tolerated in children having previously received a full course of anti-HBs vaccine in infancy as part of EPI. </plain></SENT>
<SENT sid="562" pm="."><plain>The RTS,S/AS01E formulation showed a trend towards less local reactogenicity and demonstrated higher immunogenicity for anti-CS antibodies. </plain></SENT>
<SENT sid="563" pm="."><plain>The 3 dose schedules were more immunogenic than 2 dose schedules with AUC analyses for anti-CS antibody levels and were comparable between the 0,1,2- and 0,1,7-month RTS,S/AS01E schedules. </plain></SENT>
<SENT sid="564" pm="."><plain>In summary, this study supports further evaluation of the RTS,S/AS01E candidate vaccine with both 0,1,2- and 0,1,7-month schedules in infants, and when co-administered with standard EPI antigens. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="565" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0007302.s001"><label>Checklist S1</label><caption><p><text><SENT sid="566" pm="."><plain>CONSORT Checklist </plain></SENT>
</text></p><p><text><SENT sid="567" pm="."><plain>(0.06 MB DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0007302.s001.doc"><caption><p><text><SENT sid="568" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007302.s002"><label>Protocol S1</label><caption><p><text><SENT sid="569" pm="."><plain>Trial Protocol </plain></SENT>
</text></p><p><text><SENT sid="570" pm="."><plain>(1.04 MB PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0007302.s002.pdf"><caption><p><text><SENT sid="571" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="572" pm="."><plain>We thank the participants and their parents, the community members and the Chiefs in the Kintampo and Agogo traditional areas, the Management and Staff of KNUST/KCCR/SMS, Agogo Presbyterian Hospital, Komfo Anokye Teaching Hospital, Kintampo Municipal Hospital, Ghana Health Service; the Kintampo North and South Health Directorates, KHRC, LSHTM, PATH Malaria Vaccine Initiative (MVI), INDEPTH, Malaria Clinical Trials Alliance (MCTA) and the Bill and Melinda Gates Foundation. </plain></SENT>
<SENT sid="573" pm="."><plain>We are grateful to the DSMB, chaired by Prof Malcolm Molyneux, the local safety monitors, Drs Sam Newton and Alex Manu in Kintampo and Dr Plange-Rhule in Kumasi as well as the ethics committees of the Ghana Health Service, Kintampo Health Research Centre, SMS/KNUST, LSHTM, WIRB and the FDB, Ghana. </plain></SENT>
<SENT sid="574" pm="."><plain>We also thank the following people whose support and service made this study possible: A Enimil, SB Nguah, U Irle, JT Bawa, T Kruppa, F Prempeh, M Buerhlen, K Fahndrich, LD Owusu, MAA Sarfo, AP Boakye-Yiadom, A Agyekum, B Nkrumah, L Badu, E Anane-Sarpong, W Akwaboah, Samuel Agrah, Livesy Abokyi, Akua Agyeman-Budu, Charles Zandoh, Seeba Amenga-Etego, Robert Adda and Sulemana Abubakari. </plain></SENT>
<SENT sid="575" pm="."><plain>Thanks to the Malaria Project Team in GSK, in particular, S Corachan, N Annez, K Hallez, D Beauport, S Benns*, S Pranesh, C Swysen, J Thonnard, M-C Uwamwezi and L Vigneron. </plain></SENT>
<SENT sid="576" pm="."><plain>(*indicates professional writer). </plain></SENT>
<SENT sid="577" pm="."><plain>Kintampo Health Research Centre (KHRC) is a member-site of the INDEPTH network. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="578" pm="."><plain>We would also like to thank the DSMB members: Malcolm Molyneux (DSMB Chairperson), Malaria Project and Wellcome Trust Centre, Blantyre, Malawi; Zulfiqarali Premji, School of Public Health and Social Sciences, Dar-Es-Salaam, Tanzania; Kojo Koram, Noguchi Memorial Institute for Medical Research, Legon, Ghana; Tom Doherty, London School of Hygiene and Tropical Medicine, London, United Kingdom; Juanita Hatcher, Alberta Health Services, Edmonton, Canada. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="579" pm="."><plain>Competing Interests: J Vekemans, O Ofori-Anyinam, A Leach, M Lievens, M Demoitie, M-C Dubois, J Cohen are currently employed by GSK Biologicals. </plain></SENT>
<SENT sid="580" pm="."><plain>WR Ballou was employed by GSK Biologicals at the time the study was conducted. </plain></SENT>
<SENT sid="581" pm="."><plain>O Ofori-Anyinam, A Leach, M-C Dubois and J Cohen currently hold shares in GSK Biologicals. </plain></SENT>
<SENT sid="582" pm="."><plain>J Cohen and WR Ballou are both inventors on patents relating to malaria vaccines. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="583" pm="."><plain>Funding: This study was supported by grants from PATH Malaria Vaccine Initiative and GlaxoSmithKline Biologicals. </plain></SENT>
<SENT sid="584" pm="."><plain>PATH MVI and GSK Biologicals were involved in study design, interpretation of the data and manuscript review. </plain></SENT>
<SENT sid="585" pm="."><plain>This article describes analyses that were undertaken at GSK. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0007302-Breman1"><text><SENT sid="586" pm="."><plain>1 BremanJGEganAKeuschGT 2001 Introduction and Summary. </plain></SENT>
<SENT sid="587" pm="."><plain>The intolerable burden of malaria: a new look at the numbers. American Journal of Tropical Medicine and Hygiene 64 (1, 2) S iv vii 11425185 </plain></SENT>
</text></ref><ref id="pone.0007302-Sachs1"><text><SENT sid="588" pm="."><plain>2 SachsJD 2002 A new global effort to control malaria. Science 298(5591) 122 4 12364788 </plain></SENT>
</text></ref><ref id="pone.0007302-Stewart1"><text><SENT sid="589" pm="."><plain>3 StewartVAMcGrathSMWalshDSDavisSHessAS 2006 Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42–43) 6483 6492 16904798 </plain></SENT>
</text></ref><ref id="pone.0007302-Kester1"><text><SENT sid="590" pm="."><plain>4 KesterKE 2005 Malaria-027 trial results. WRAIR sponsored satellite presentation at ASTMH Philadelphia USA 11-15th December 2005  </plain></SENT>
</text></ref><ref id="pone.0007302-Polhemus1"><text><SENT sid="591" pm="."><plain>5 PolhemusME 2006 MAL 044 phase IIb clinical trial comparing two GSK adjuvant formulations AS01B and AS02A at the Walter Reed Project, Kisumu, Kenya. WRAIR sponsored satellite presentation at ASTMH Atlanta GA USA 13–16th November 2006  </plain></SENT>
</text></ref><ref id="pone.0007302-Alonso1"><text><SENT sid="592" pm="."><plain>6 AlonsoPLSacarlalJAponteJJLeachLMaceteE 2005 Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 2012 18 16338450 </plain></SENT>
</text></ref><ref id="pone.0007302-Macete1"><text><SENT sid="593" pm="."><plain>7 MaceteEVSacarlalJAponteJJLeachANaviaMM 2007 Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials 8 11 17386091 </plain></SENT>
</text></ref><ref id="pone.0007302-Lell1"><text><SENT sid="594" pm="."><plain>8 LellB 2007 A randomized, observer-blind trial to compare safety and immunogenicity of two adjuvanted RTS,S anti-malaria vaccine candidates in Gabonese children. Presented at ASTMH Philadelphia USA November 5–7th 2007  </plain></SENT>
</text></ref><ref id="pone.0007302-Abdulla1"><text><SENT sid="595" pm="."><plain>9 AbdullaSOberholzerRJumaOKubhojaSMacheraF 2008 Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. NEJM 359 2533 44 19064623 </plain></SENT>
</text></ref><ref id="pone.0007302-Bejon1"><text><SENT sid="596" pm="."><plain>10 BejonPLusinguJOlotuALeachALievensM 2008 Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. NEJM 359 2521 32 19064627 </plain></SENT>
</text></ref><ref id="pone.0007302-Bonhoeffer1"><text><SENT sid="597" pm="."><plain>11 BonhoefferJMenkesJGoldMde Souza-BritoGFisherM 2004 The Brighton Collaboration Seizure Working Group. </plain></SENT>
<SENT sid="598" pm="."><plain>Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 557 562 14741144 </plain></SENT>
</text></ref><ref id="pone.0007302-WHOIVR1"><text><SENT sid="599" pm="."><plain>12 WHO/IVR 2005 State of the art of vaccine research and development: Initiative for vaccine research World Health Organization, January 2005.  </plain></SENT>
</text></ref><ref id="pone.0007302-Bojang1"><text><SENT sid="600" pm="."><plain>13 BojangKAMilliganPJMPinderMVigneronLAllouecheA 2001 Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomized trial. The Lancet 358 1927 34  </plain></SENT>
</text></ref><ref id="pone.0007302-Kester2"><text><SENT sid="601" pm="."><plain>14 KesterKEMcKinneyDATornieporthNOckenhouseCFHeppnerDG 2007 RTS,S malaria vaccine evaluation group. a phase IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 25 5359 66 17574311 </plain></SENT>
</text></ref><ref id="pone.0007302-Doherty1"><text><SENT sid="602" pm="."><plain>15 DohertyJFPinderMTornieporthNCartonCVigneronL 1999 A phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SABAS2, in semi-immune adults in The Gambia. Am J Trop Med Hyg 61 865 868 10674660 </plain></SENT>
</text></ref><ref id="pone.0007302-Stoute1"><text><SENT sid="603" pm="."><plain>16 StouteJAHeppnerDGJrMasonCJSianglaJOpolloMO 2006 Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of Western Kenya. Am J Trop Med Hyg 75 166 70 16837726 </plain></SENT>
</text></ref><ref id="pone.0007302-Alonso2"><text><SENT sid="604" pm="."><plain>17 AlonsoPLSacarlalJAponteJJLeachAMaceteE 2004 Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 364 1411 1420 15488216 </plain></SENT>
</text></ref><ref id="pone.0007302-Sacarlal1"><text><SENT sid="605" pm="."><plain>18 SacarlalJAponteJJAidePMandomandoIBassatQ 2008 Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26 174 184 18069097 </plain></SENT>
</text></ref><ref id="pone.0007302-Alonso3"><text><SENT sid="606" pm="."><plain>19 AlonsoPLSacarlalJAponteJJLeachAMaceteE 2005 Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 2012 18 16338450 </plain></SENT>
</text></ref><ref id="pone.0007302-Bojang2"><text><SENT sid="607" pm="."><plain>20 BojangKOlodudeFPinderMOfori-AnyinamOVigneronL 2005 Phase I safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23 (32) 4148 57 15964483 </plain></SENT>
</text></ref><ref id="pone.0007302-Macete2"><text><SENT sid="608" pm="."><plain>21 MaceteEAponteJJGuinovartCSacarlalJOfori-AnyinamO 2007 Safety, reactogenicity and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1 to 4 years in Mozambique. Trop Med Int Health 12(1) 37 46 17207146 </plain></SENT>
</text></ref><ref id="pone.0007302-Archampong1"><text><SENT sid="609" pm="."><plain>22 ArchampongEQNaaederSBDarkoR Changing pattern of intestinal obstruction in Accra, Ghana. Hepatogastroenterology 2000; 47 185 193  </plain></SENT>
</text></ref><ref id="pone.0007302-Hadler1"><text><SENT sid="610" pm="."><plain>23 HadlerSCde MonzonMALugoDRPerezM 1989 Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 7(2) 106 10 2526419 </plain></SENT>
</text></ref><ref id="pone.0007302-Jilg1"><text><SENT sid="611" pm="."><plain>24 JilgWSchmidtMDeinhardtF 1989 Four-year experience with a recombinant vaccine. Infection 17 70 6 2714860 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
